Group 1 - The core point of the article highlights the performance of the Hong Kong Stock Connect Innovative Drug ETF managed by Southern Fund Management, which saw a 3.00% increase in value on January 7, with a trading volume of 107 million yuan [1] - The fund's total shares increased by 3 million to reach 1.862 billion, with a notable increase of 179 million shares over the past 20 trading days [1] - The latest net asset value of the fund is calculated to be 1.631 billion yuan, and its performance benchmark is the Guozheng Hong Kong Stock Connect Innovative Drug Index, adjusted for valuation exchange rates [1] Group 2 - Since its establishment on September 12, 2025, the fund has reported a return of -12.45%, while its return over the past month is -1.10% [1] - The fund is managed by Zhang Qisi and Ye Zhenan, indicating a focus on innovative drug investments within the Hong Kong market [1]
1月7日港股通创新药ETF南方（159297）份额增加300.00万份，最新份额18.62亿份，最新规模16.31亿元
Xin Lang Cai Jing·2026-01-08 04:02